This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

3-O-sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer’s neurodegeneration

ArrestAD

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimer’s disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure...
Funding Programme
Start Date
End Date
Total Funding
€ 3 991 096
European Countries Involved

40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

BRIGHT

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

A blood based biomarker identifying early Alzheimer Disease's pathology

VERDAD

Alzheimer’s Disease (AD) poses an unbearable impact in patients’ life, through progressive loss of cognitive capacities and overall quality of life. In Europe alone, there is currently a €280 bn yearly expenditure related to AD and ~10% of the population above 65 years old is currently affected by the disease, a figure that is expected to triple in...
Funding Programme
Start Date
End Date
Total Funding
€ 3 365 416
European Countries Involved

A Drug Discovery and Target Identification Screening Platform for Age-Associated Neurodegenerative Disorders

NeuronAgeScreen

Battling human neurodegenerative pathologies, and their pervasive societal impact, is a global multi-billion Euro enterprise. Ageing is universally associated with marked decrease of neuronal function and higher susceptibility to neurodegeneration. In human populations, this is manifested as an ever-increasing prevalence of devastating...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

A MULTI-SPECTROSCOPIC APPROACH TO PROBE AMYLOID AGGREGATION AT BIOLOGICAL SURFACES

MultiSpecAMYLOID

Treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s syndrome, is one of the biggest challenges of nowadays medicine. The success of the curing strongly depends on our understanding of chemical processes involved in developing these diseases. From a chemical point of view, these diseases are determined by uncontrolled...

Funding Programme
Start Date
End Date
Total Funding
€ 130 780
European Countries Involved

A multimodal approach to accelerate drug discovery and development in Alzheimer’s disease

MAP-AD

Alzheimer’s disease (AD) is a major societal challenge, impacting up to one third of the population over 85 years old. The European Commission and various international bodies have repeatedly fostered research initiatives to prevent the development or stem the progression of the disease. Several recent phase 3 clinical trials have failed to show...
Funding Programme
Start Date
End Date
Total Funding
€ 257 620
European Countries Involved

A new brain-dedicated Positron Emission Tomography (PET) system to identify β-amyloid biomarker for the early diagnosis of Alzheimer’s disease and other causes of cognitive decline

CAREMIBRAIN

ONCOVISION is a Spanish SME specialised in design, development, production and commercialisation of organ-dedicated PET systems. Our company submits the present business innovation project with the overall objectives of (1) marketing an innovative brain-dedicated PET system to early diagnosis of Alzheimer’s disease (AD) and other causes of...
Funding Programme
Start Date
End Date
Total Funding
€ 4 393 596
European Countries Involved

A next-generation platform for catalysing pre-clinical development of drugs against Alzheimer’s and other degenerative diseases of old-age

NEW-AGE

Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditions including Alzheimer’s and Parkinson’s, which have been described as the greatest unmet need facing modern medicine...

Funding Programme
Start Date
End Date
Total Funding
€ 149 961
European Countries Involved

A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

variaTECT

Alzheimer’s Disease (AD) is the most prevalent cognitive disorder and progressively leads to complete brain dysfunction and degeneration. The number of people living with Alzheimer’s worldwide is now estimated at 46M, with this figure set to almost double by 2030 and more than triple by 2050 due to population aging. Current methods for early...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

A real-time and continuous brain monitoring system to record and track brain activity and extract biomarkers for neurological conditions

NS System

Neurological disorders, ranging from epilepsy, autism, dementias, Alzheimer’s and Parkinson’s diseases affect 1B people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these numbers are expected to drastically grow (3% per year) increasing the population affected by brain disorders. Many neurological...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

A Single-Molecule Technology for Resolving Chaperone Action in Neurodegenerative Diseases

MicroSPARK

A range of debilitating neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, arise from the formation of amyloidogenic protein aggregates. Molecular chaperones can counteract aggregate formation, but their molecular action mechanisms remain poorly understood. This is chiefly due to the fundamental challenge of resolving...
Funding Programme
Start Date
End Date
Total Funding
€ 212 934
European Countries Involved

A smart, hybrid neural-computo device for drug discovery

NEUREKA

NEUREKA will bring a paradigm shift in drug discovery for neurological diseases, a sector that suffers multiple, repeated failures exacerbating the economical and societal burden of these incurable diseases. It will do so by addressing a crucial shortcoming: the lack of in vitro systems faithfully reproducing brain pathology that enable the...
Funding Programme
Start Date
End Date
Total Funding
€ 2 776 705
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).